Divalproex Sodium
Product Images NDC 55648-975

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55648-975). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label (Divalproex Dr Tablets Container Labels 125 mg 100 Tab)

Bottle Label (Divalproex Dr Tablets Container Labels 125 mg 100 Tab)
This is a product description for Divalproex Sodium, which is a medication in tablet form used to treat seizures, migraines, and bipolar disorder. The tablets are delayed-release and contain 125 mg of Valproic acid activity. It is important to dispense the medication with a patient information sheet and store it in a light-resistant container. The medication is manufactured by Wockhardt Limited in Mumbai, India and distributed by Wockhardt USA LLC in Parsippany, NJ.*
FDA Label Image

Bottle Label (Divalproex Dr Tablets Container Labels 250 mg 500 Tab)

Bottle Label (Divalproex Dr Tablets Container Labels 250 mg 500 Tab)
This is a description of a medication called Divalproex Sodium, which comes in the form of delayed-release tablets. These tablets contain Valproic Acid Activity and are dispensed with a patient information sheet. This medication is used to treat various medical conditions, although it is not specified which ones. Each tablet contains Divalproex sodium equivalent to 250 mg of Valproic acid, and it is recommended to store the medication in a USP tight, light-resistant container stored at 20°-25°C (68*77°F) (See USP Controlled Room Temperature). The manufacturer of this medicine is Wockharat, and it is distributed by a company located in Parsippany, NJ 07054. This description does not include any non-English characters, therefore, no exclusion is required.*
FDA Label Image

Bottle Label (Divalproex Dr Tablets Container Labels 500 mg 500 Tab)

Bottle Label (Divalproex Dr Tablets Container Labels 500 mg 500 Tab)
This is a description of a medication called Divalproex Sodium Delayed-Release Tablets USP. Each tablet contains 500 mg of Valproic Acid Activity. This medication is dispensed in a USP tight, light-resistant container and should be stored between 20°-25°C (68°-77°F). It is manufactured by Wockhardt Limited in Mumbai, India, and distributed by Wockhardt USA LLC in Parsippany, NJ.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
This is a description of two studies involving Placebo Divalproex Sodium delayed-release tablets. No further information is available.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
This text presents a graph showing the % reduction in CPS rate for patients taking Divalproex Sodium Delayed-Release Tablets. It shows that 50% of the patients experienced an improvement in their condition, while some others had no change or even worsening.*
FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
FDA Label Image

Strecture (Structure01)

Strecture (Structure01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.